ValuEngine upgraded shares of Gilead Sciences (NASDAQ:GILD) from a buy rating to a strong-buy rating in a research report report published on Thursday morning.

A number of other equities analysts have also weighed in on GILD. Barclays restated an overweight rating and issued a $90.00 price objective on shares of Gilead Sciences in a report on Wednesday, October 11th. Vetr upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $91.98 price objective for the company in a report on Friday, October 13th. Zacks Investment Research lowered shares of Gilead Sciences from a hold rating to a sell rating in a report on Wednesday, October 18th. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a buy rating in a report on Thursday, October 19th. Finally, William Blair restated a buy rating on shares of Gilead Sciences in a report on Thursday, October 19th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of Buy and a consensus target price of $86.56.

Gilead Sciences (NASDAQ GILD) opened at $79.32 on Thursday. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $89.54. The firm has a market cap of $103,613.26, a P/E ratio of 22.79, a P/E/G ratio of -1.75 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period in the previous year, the business earned $2.70 EPS. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. analysts anticipate that Gilead Sciences will post 6.41 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 59.77%.

In other news, Chairman John C. Martin sold 50,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.56, for a total transaction of $4,178,000.00. Following the completion of the sale, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the sale, the executive vice president now directly owns 62,738 shares of the company’s stock, valued at approximately $5,239,250.38. The disclosure for this sale can be found here. In the last ninety days, insiders sold 578,333 shares of company stock valued at $44,100,508. 1.30% of the stock is currently owned by insiders.

Several hedge funds have recently modified their holdings of GILD. Welch Investments LLC bought a new position in Gilead Sciences in the 3rd quarter worth $108,000. Wealthcare Advisory Partners LLC bought a new position in Gilead Sciences in the 3rd quarter worth $133,000. Horan Capital Advisors LLC. bought a new position in Gilead Sciences in the 3rd quarter worth $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Gilead Sciences in the 2nd quarter worth $147,000. Finally, Hanson & Doremus Investment Management boosted its holdings in Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the period. 75.84% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/gilead-sciences-gild-raised-to-strong-buy-at-valuengine/1859296.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.